Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

Xencor (XNCR) Misses Q4 EPS by 6c, Revenues Miss

February 24, 2020 4:13 PM EST

Xencor (NASDAQ: XNCR) reported Q4 EPS of ($0.47), $0.06 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.52 million versus the consensus estimate of $14.27 million.

Throughout 2019 we made important progress advancing and expanding our portfolio. At ASH, we presented initial data from the ongoing Phase 1 study of plamotamab in patients with B cell malignancies, in which our CD20 x CD3 bispecific antibody demonstrated that it was generally well tolerated with encouraging clinical activity in early dose-escalation cohorts. We also... More